Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Oxaprozin-induced fulminant hepatitis

P P Purdum1, S L Shelden, J W Boyd

  • 1Department of Internal Medicine, Medical College of Virginia, Virginia Commonwealth University, Richmond.

The Annals of Pharmacotherapy
|October 1, 1994
PubMed
Summary

Oxaprozin, a nonsteroidal antiinflammatory drug (NSAID), has been linked to rare cases of severe liver injury. This study reports the first instance of oxaprozin-induced fulminant hepatic failure, emphasizing the need for liver function monitoring during NSAID therapy.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Long-term clearance of hepatitis C virus following interferon α-2b or peginterferon α-2b, alone or in combination with ribavirin.

Journal of viral hepatitis·2013
Same author

Optimized threshold for serum HCV RNA to predict treatment outcomes in hepatitis C patients receiving peginterferon alfa-2a/ribavirin.

Journal of viral hepatitis·2012
Same author

Clinical trial: the efficacy and safety of oral PF-03491390, a pancaspase inhibitor - a randomized placebo-controlled study in patients with chronic hepatitis C.

Alimentary pharmacology & therapeutics·2010
Same author

Quantitative tests of liver function measure hepatic improvement after sustained virological response: results from the HALT-C trial.

Alimentary pharmacology & therapeutics·2008
Same author

The spectrum of hepatic functional impairment in compensated chronic hepatitis C: results from the Hepatitis C Anti-viral Long-term Treatment against Cirrhosis Trial.

Alimentary pharmacology & therapeutics·2008
Same author

Histological benefits of virological response to peginterferon alfa-2a monotherapy in patients with hepatitis C and advanced fibrosis or compensated cirrhosis.

Alimentary pharmacology & therapeutics·2008

Area of Science:

  • Hepatology
  • Pharmacology
  • Toxicology

Background:

  • Nonsteroidal antiinflammatory drugs (NSAIDs) are widely used for pain and inflammation.
  • While generally safe, NSAIDs can cause adverse effects, including liver injury (transaminitis).
  • Oxaprozin is a long-acting NSAID with known potential for hepatic transaminase elevation.

Observation:

  • A 56-year-old woman presented with acute liver failure.
  • Extensive workup excluded other causes of liver injury.
  • Oxaprozin use for two months prior to admission was the only significant finding.
  • Liver biopsy revealed drug-induced hepatic injury, similar to diclofenac-induced cases.

Findings:

  • This case represents the first documented instance of oxaprozin-induced fulminant hepatic failure.

Related Experiment Videos

  • Oxaprozin, like other NSAIDs, can cause severe hepatotoxicity.
  • The severity of liver injury may be associated with NSAID duration of use and patient factors.

    • Implications:

    • Clinicians should be aware of the potential for severe liver injury with oxaprozin.
    • Monitoring of liver function enzymes is crucial during NSAID therapy, especially in the elderly or those on concurrent hepatotoxic medications.
    • This rare but serious adverse event underscores the importance of vigilant pharmacovigilance for NSAIDs.